AI in Drug Discovery Market to grow at a CAGR of 23.9% during 2026 to 2035; Driven by Increasing Adoption of Artificial Intelligence Technologies and Rising Demand for Faster Drug Development

AI in Drug Discovery Market Highlights

The AI in Drug Discovery Market was valued at USD 2.81 billion in 2025 and is projected to grow from USD 3.48 billion in 2026 to USD 23.95 billion by 2035, registering a CAGR of 23.9% during the forecast period.

According to MRFR, the leading firms within the Global Artificial Intelligence (AI) in Drug Discovery Market are IBM, NuMedii, Atomwise, Exscientia, Recursion Pharmaceuticals, Strateos, Insilico Medicine, Google DeepMind, Zebra Medical Vision, Biorelate, Microsoft, BenevolentAI, and CureMetrix.

The need for more efficient and cheaper ways to develop drugs alongside more investments in biotechnology and personalized medicine is helping the market grow. Predictive analytics and high-throughput screening powered by artificial intelligence help laser focus searches for promising drug candidates, molecular structures are optimized, and clinical trial failures are reduced when AI is brought into the process. 

AI is changing pharmaceutical research for the better, especially for target identification, lead optimization, drug repurposing, and clinical trial management. Regulatory agencies are endorsing AI in drug development and for good reason, since it improves the safety of drugs and shortens the approval process. 

Pharmaceutical companies are also using machine learning and natural language processing when coupled with biomedical research to develop new therapeutics and improve efficiency in drug development. Partnerships between AI developers and pharmaceutical companies are also helping innovation in the industry. 

As an example, Exscientia has a partnership with Bristol Myers Squibb worth more than 1.2 billion dollars that intends to use AI for multi-targeted drug discovery. This demonstrates the commercial importance AI is gaining in drug development and demonstrates the clinical importance AI is gaining in drugs as well. 

Segment Analysis

There are five ways to look at the market for AI in drug discovery applications for the purpose of gathering information in business analytics: Application, Technology, End Use, and Region analysis.

By Application

The different types are Target Identification, Lead Optimization, Drug Repurposing, Clinical Trials, and Preclinical Testing. The largest market share is held by Target Identification, which is expected to increase from USD 1.1 billion in 2024 to USD 6.3 Billion by 2035, mostly due to its importance in early drug development.

The Lead Optimization segment is anticipated to grow from USD 1.0 Billion in 2024 to USD 5.5 Billion by 2035 due to increased utilization of AI in optimizing molecular interactions and minimizing off-target effects. The Drug Repurposing segment is anticipated to grow to USD 4.5 Billion by 2035 and is increasingly utilizing AI to find alternative uses for existing drugs in a cost and time-efficient manner regarding R&D.

By Technology

The types are Machine Learning, Deep Learning, Natural Language Processing (NLP), Knowledge Graphs, and Robotic Process Automation (RPA). Machine Learning is popular and is used for predictive modeling and compound screening. Deep Learning is expected to grow the fastest due to new advances in drug discovery frameworks that use neural networks.

By End Use

The market is segmented into Pharmaceutical Companies, Biotechnology Firms, Research Institutions, and Academic Institutions. The Largest market share was held by the pharmaceutical companies’ sector in 2024 because large pharmaceutical companies are using artificial intelligence to improve drug development and research. The largest growth would accrue in biotechnology firms. There is a growth in artificial intelligence technology in design, precision medicine and early-stage molecule development.

Market Region Analysis

The artificial intelligence in the drug development market is divided by region: North America, Europe, Asia Pacific, South America and the Middle East & Africa.

North America held the largest market share valued at USD 1.76 Billion in 2024 and is expected to grow to USD 10.11 Billion by 2035 because of strong research in artificial intelligence, large pharmaceutical companies and favourable regulatory frameworks.

After North America, Europe held the second largest market at USD 1.1 Billion in 2024 and is expected to grow up to USD 6.3 Billion by 2035. This is because of greater investment in artificial intelligence clinical trials and collaboration of biotech companies and artificial intelligence start-ups.

The Asia Pacific has the fastest expected growth, going from USD 0.92 Billion in 2024 to USD 5.32 Billion by 2035. This is because of an increase in healthcare spending, the use of artificial intelligence in research, and government support of digital health.

Furthermore, South America and the Middle East and Africa stand to benefit immensely from international pharmaceutical industry partnerships, highlighting the potential to grow to USD 1.3 billion and USD 1.87 billion, respectively, by 2035.

Study Highlights

• Machine learning holds the dominant position in the AI in Drug Discovery Market, representing a 28.2% CAGR through 2035.


• Natural language processing and computer vision applications are gaining traction in literature mining and histopathology analysis.


• North America generated approximately USD 1.18 billion in 2025 revenue, maintaining its lead across the AI in Drug Discovery Market.


• Asia-Pacific is projected to reach USD 6.21 billion by 2035, representing the fastest regional expansion trajectory.